Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Endometrial Cancer
•
Medical Oncology
What starting dose of lenvatinib are you ultilizing in recurrent endometrial cancer patients initiating lenvatinib/pembro?
Answer from: at Academic Institution
I start with 20 mg daily. I base this on the recent study by Makker and colleagues
Sign in or Register to read more
8046
Related Questions
How would you sequence adjuvant chemo-immunotherapy (paclitaxel/carbo/pembro or paclitaxel/carbo/dostarlimab) with EBRT and vaginal cuff brachytherapy in advanced uterine cancer that meets clinical criteria for both EBRT and chemo-IO?
Would you add olaparib to maintenance immunotherapy for a patient with recurrent MMR-proficient, HER2-negative serous endometrial carcinoma?
Would you consider trying Pembrolizumab + Lenvatinib after progression on first-line Carboplatin + Paclitaxel + Immunotherapy for metastatic endometrial cancer?
Given the negative results of GOG-0238 but the positive results of the RUBY trial, how do you manage isolated vaginal cuff recurrence of endometrial cancer?
How would you manage a POLE mutated, p53 abnormal IA myoinvasive carcinosarcoma of the endometrium with no LVSI?
Do you screen for immune-related adrenal insufficiency for patients on immune checkpoint inhibitors?
What adjuvant treatment would you recommend for a patient with FIGO 2023 IIIB2 endometrioid endometrial adenocarcinoma (Grade 3, p53mut, MMR proficient), metastatic to the uterine serosa, bilateral ovaries, and anterior peritoneal reflection?
Do you perform routine pelvic exams on patients undergoing active treatment for gynecologic cancer without GYN symptoms?
How do you manage a FIGO stage IB dedifferentiated endometrial carcinoma that is MMR deficient and p53 wt?
Would you offer trastuzumab-deruxtecan for a metastatic ovarian cancer patient with good performance status whose tumor stains 1+ on IHC for HER2 and who has exhausted all treatment options?